AlloVir_Logo_FullColor[2].png
AlloVir Reports Third Quarter 2020 Financial Results
November 10, 2020 07:00 ET | AlloVir Inc.
- Completed initial public offering raising $317.7M in gross proceeds - Viralym-M (multi-virus-specific T cell therapy) registrational study in lead indication in virus-associated hemorrhagic...
AlloVir_Logo_FullColor[2].png
AlloVir Announces Oral Data Presentations at 62nd American Society of Hematology Annual Meeting
November 04, 2020 13:33 ET | AlloVir Inc.
CAMBRIDGE, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced that it will present three abstracts as oral presentations that...
AlloVir_Logo_FullColor[2].png
Data to Be Presented at IDWeek™ 2020 Demonstrate the Economic and Clinical Burden of Respiratory and Multi-Virus Infections in Allogeneic Hematopoietic Cell Transplantation Recipients
October 21, 2020 07:30 ET | AlloVir Inc.
CAMBRIDGE, Mass., Oct. 21, 2020 (GLOBE NEWSWIRE) -- AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced that health outcomes analyses to be presented at IDWeek™ 2020...
AlloVir_Logo_FullColor[2].png
AlloVir Announces the FDA Clearance of Investigational New Drug Application (IND) for ALVR109 for the Treatment of High-Risk COVID-19 Patients
September 17, 2020 09:49 ET | AlloVir Inc.
- ALVR109 is an allogeneic, off-the-shelf virus-specific T cell therapy candidate designed to target SARS-CoV-2 for high-risk COVID-19 patients - Proof-of-concept clinical trial with ALVR109 to...
AlloVir_Logo_FullColor[2].png
AlloVir Appoints Ercem Atillasoy, M.D., as Chief Regulatory and Safety Officer
September 08, 2020 16:15 ET | AlloVir Inc.
CAMBRIDGE, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced the appointment of Ercem Atillasoy, M.D., as the company’s Chief...
AlloVir_Logo_FullColor[2].png
AlloVir Reports Second Quarter 2020 Financial Results
September 02, 2020 07:30 ET | AlloVir Inc.
CAMBRIDGE, Mass., Sept. 02, 2020 (GLOBE NEWSWIRE) -- AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today reported financial results for the second quarter ended June 30, 2020. ...
AlloVir_Logo_FullColor[2].png
AlloVir to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
August 25, 2020 07:30 ET | AlloVir Inc.
CAMBRIDGE, Mass., Aug. 25, 2020 (GLOBE NEWSWIRE) -- AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate overview at the virtual Morgan Stanley 18th...
AlloVir_Logo_FullColor[2].png
AlloVir Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
August 03, 2020 16:30 ET | AlloVir Inc.
CAMBRIDGE, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced the closing of its upsized initial public offering of...
AlloVir_Logo_FullColor[2].png
AlloVir Announces Pricing of Upsized Initial Public Offering
July 30, 2020 07:32 ET | AlloVir Inc.
CAMBRIDGE, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced the pricing of its upsized initial public offering of...